| Jabbar Ben Zafar, DO | |
|
3 Penns Trl, Newtown, PA 18940-1812 | |
| (215) 504-1761 | |
| Not Available |
| Full Name | Jabbar Ben Zafar |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 34 Years |
| Location | 3 Penns Trl, Newtown, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649214495 | NPI | - | NPPES |
| 6225209 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MB57866 (New Jersey) | Secondary |
| 207Q00000X | Family Medicine | OS15416 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Capital Health Medical Center - Hopewell | Pennington, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Capital Health Medical Group | 7618264532 | 364 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.
Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for peginesatide (formerly known as Hematide™) for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.
InvestorSoup.com announces an investment report featuring Cyclacel Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
On October 9, 2015, the board of directors of the Chemical Heritage Foundation (CHF) in Philadelphia approved a merger with the Life Sciences Foundation (LSF) of San Francisco. On October 11, the Life Sciences Foundation board approved the same plan.
› Verified 5 days ago
| Entity Name | Capital Health Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437516887 PECOS PAC ID: 7618264532 Enrollment ID: O20161007001348 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.
Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for peginesatide (formerly known as Hematide™) for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.
InvestorSoup.com announces an investment report featuring Cyclacel Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
On October 9, 2015, the board of directors of the Chemical Heritage Foundation (CHF) in Philadelphia approved a merger with the Life Sciences Foundation (LSF) of San Francisco. On October 11, the Life Sciences Foundation board approved the same plan.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jabbar Ben Zafar, DO 3 Penns Trl, Newtown, PA 18940-1812 Ph: (215) 504-1761 | Jabbar Ben Zafar, DO 3 Penns Trl, Newtown, PA 18940-1812 Ph: (215) 504-1761 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.
Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for peginesatide (formerly known as Hematide™) for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.
InvestorSoup.com announces an investment report featuring Cyclacel Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
On October 9, 2015, the board of directors of the Chemical Heritage Foundation (CHF) in Philadelphia approved a merger with the Life Sciences Foundation (LSF) of San Francisco. On October 11, the Life Sciences Foundation board approved the same plan.
› Verified 5 days ago
Dr. Michael B Fischer, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2950 South Eagle Rd., Newtown, PA 18940 Phone: 215-504-9255 Fax: 215-504-9260 | |
Dr. Barbara Mirth-jacobelli, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1382 Newtown Langhorne Rd, Newtown, PA 18940 Phone: 215-968-9110 | |
Joseph Kipp, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 11 Friends Ln, Suite 101, Newtown, PA 18940 Phone: 215-579-1300 Fax: 215-579-0150 | |
John M Lawless Jr., DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 11 Friends Ln, Suite 101, Newtown, PA 18940 Phone: 215-579-1300 Fax: 215-579-0150 | |
Jane Flynn-abdalla, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3 Penns Trl, Newtown, PA 18940 Phone: 215-504-1761 Fax: 215-504-1721 | |
Randi Banner, CRNP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1382 Newtown Langhorne Rd, Newtown, PA 18940 Phone: 215-504-6809 Fax: 215-579-0266 | |
Dr. Barbara M Saracino, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 638 Newtown Yardley Rd Ste 2e, Newtown, PA 18940 Phone: 215-968-1616 Fax: 215-860-1976 |